Biodexa Pharmaceuticals Plc

DB:5MP0 Rapporto sulle azioni

Cap. di mercato: €4.0m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Biodexa Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Biodexa Pharmaceuticals' CEO is Stephen Stamp, appointed in Sep 2019, has a tenure of 3.58 years. total yearly compensation is £237.90K, comprised of 99.4% salary and 0.6% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth €105.82. The average tenure of the management team and the board of directors is 2.3 years and 6 years respectively.

Informazioni chiave

Stephen Stamp

Amministratore delegato

UK£237.9k

Compenso totale

Percentuale dello stipendio del CEO99.4%
Mandato del CEO3.6yrs
Proprietà del CEO0.003%
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Stephen Stamp rispetto agli utili di Biodexa Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2022n/an/a

-UK£5m

Mar 31 2022n/an/a

-UK£5m

Dec 31 2021UK£329kUK£187k

-UK£5m

Sep 30 2021n/an/a

-UK£7m

Jun 30 2021n/an/a

-UK£8m

Mar 31 2021n/an/a

-UK£15m

Dec 31 2020UK£193kUK£175k

-UK£22m

Jun 30 2020n/an/a

-UK£22m

Mar 31 2020n/an/a

-UK£16m

Dec 31 2019UK£207kUK£50k

-UK£9m

Compensazione vs Mercato: Stephen's total compensation ($USD296.50K) is below average for companies of similar size in the German market ($USD444.06K).

Compensazione vs guadagni: Stephen's compensation has been consistent with company performance over the past year.

AMMINISTRATORE DELEGATO

Stephen Stamp (60 yo)

3.6yrs

Mandato

UK£237,897

Compensazione

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Stephen Stamp
CEO, CFO3.6yrsUK£237.90k0.0026%
£ 105.8
Dmitry Zamoryakhin
Chief Scientific Officer1.8yrsUK£236.68kNessun dato
Daniel Palmer
Vice President of Technology2.3yrsNessun datoNessun dato
Vincent Holmes
VP & Head of Clinical Operationsless than a yearNessun datoNessun dato
David Benharris
President of Midatech Pharma US Inc7.3yrsNessun datoNessun dato
Fiona Sharp
Group Financial Controllerno dataNessun datoNessun dato

2.3yrs

Durata media

57yo

Età media

Gestione esperta: 5MP0's management team is considered experienced (2.3 years average tenure).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Stephen Stamp
CEO, CFO3.6yrsUK£237.90k0.0026%
£ 105.8
Simon Turton
Senior Independent Non-Executive Director8.3yrsUK£31.54k0.0029%
£ 117.0
Stephen Parker
Non-Executive Chairmanless than a yearUK£43.84kNessun dato
Daniel McCurdy
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Sijmen de Vries
Independent Non-Executive Director18.5yrsUK£31.54k0.0012%
£ 49.7
Michael Natan
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Francesco Stellaci
Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
David Male
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Lorraine O'Driscoll
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Soledad Penades
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Jean-Christophe Roux
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Silke Krol
Member of Scientific Advisory Boardno dataNessun datoNessun dato

6.0yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: 5MP0's board of directors are considered experienced (6 years average tenure).